Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
or

Novo Nordisk A/S ADR (NVO)

Novo Nordisk A/S ADR (NVO)
58.47 x 1 58.55 x 10
Post-market by (Cboe BZX)
58.33 +0.25 (+0.43%) 04/21/25 [NYSE]
58.47 x 1 58.55 x 10
Post-market 58.55 +0.22 (+0.38%) 18:10 ET
Quote Overview for Mon, Apr 21st, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
57.00
Day High
59.30
Open 58.25
Previous Close 58.08 58.08
Volume 13,407,719 13,407,719
Avg Vol 10,085,736 10,085,736
Stochastic %K 7.60% 7.60%
Weighted Alpha -60.73 -60.73
5-Day Change -6.40 (-9.89%) -6.40 (-9.89%)
52-Week Range 57.00 - 148.15 57.00 - 148.15
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 260,635,872
  • Shares Outstanding, K 4,487,532
  • Annual Sales, $ 42,108 M
  • Annual Income, $ 14,643 M
  • EBIT $ 18,609 M
  • EBITDA $ 21,380 M
  • 60-Month Beta 0.61
  • Price/Sales 6.70
  • Price/Cash Flow 16.20
  • Price/Book 13.56

Options Overview Details

View History
  • Implied Volatility 58.27% ( +5.38%)
  • Historical Volatility 55.36%
  • IV Percentile 96%
  • IV Rank 73.29%
  • IV High 70.99% on 04/08/25
  • IV Low 23.37% on 06/12/24
  • Put/Call Vol Ratio 0.65
  • Today's Volume 36,123
  • Volume Avg (30-Day) 43,790
  • Put/Call OI Ratio 0.90
  • Today's Open Interest 480,016
  • Open Int (30-Day) 474,183

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 0.91
  • Number of Estimates 4
  • High Estimate 0.94
  • Low Estimate 0.88
  • Prior Year 0.83
  • Growth Rate Est. (year over year) +9.64%

Price Performance

See More
Period Period Low Period High Performance
1-Month
57.00 +2.33%
on 04/21/25
Period Open: 76.86
76.05 -23.30%
on 03/25/25
-18.53 (-24.11%)
since 03/21/25
3-Month
57.00 +2.33%
on 04/21/25
Period Open: 81.03
93.80 -37.81%
on 02/25/25
-22.70 (-28.01%)
since 01/21/25
52-Week
57.00 +2.33%
on 04/21/25
Period Open: 122.71
148.15 -60.63%
on 06/25/24
-64.38 (-52.47%)
since 04/19/24

Most Recent Stories

More News
Down 61%, Is Novo Nordisk Stock Worth Buying on the Dip?

Novo Nordisk (NYSE: NVO) stock hit an all-time high of $148.15 in June 2024, marking a remarkable fivefold surge since 2019. Yet the stock has since plummeted 61% from its peak value.

NVO : 58.33 (+0.43%)
LLY : 818.02 (-2.61%)
Did Eli Lilly Just Say Checkmate to Novo Nordisk?

Novo Nordisk (NYSE: NVO) has seen revenue soar in recent years thanks to two drugs that have helped people around the world lose weight. The molecule is semaglutide, and it's sold under the name Ozempic...

VKTX : 23.72 (-0.92%)
NVO : 58.33 (+0.43%)
LLY : 818.02 (-2.61%)
GS : 501.36 (-1.60%)
Eli Lilly's Experimental Weight Loss Pill Succeeded in Its First Pivotal Trial. Is It Time to Buy?

More than 2 out of 5 American adults are obese, according to the Centers for Disease Control. With this figure in mind, it's no wonder Wall Street investment banks are telling anyone who will listen that...

NVO : 58.33 (+0.43%)
MS : 106.30 (-2.64%)
LLY : 818.02 (-2.61%)
Where Will Eli Lilly Be in 5 Years?

What a difference five years can make. Just look at Eli Lilly (NYSE: LLY) . In April 2020, the drugmaker stood in the shadows to some extent with companies including Johnson & Johnson, Pfizer , and Merck...

NVO : 58.33 (+0.43%)
MRK : 77.85 (-0.19%)
JNJ : 156.92 (-0.35%)
LLY : 818.02 (-2.61%)
PFE : 22.04 (-0.45%)
Why Eli Lilly Stock Is Soaring Today, While Novo Nordisk and Viking Therapeutics Slide

Eli Lilly has a plan to dominate the GLP-1 weight loss drug market -- and it's succeeding.

VKTX : 23.72 (-0.92%)
NVO : 58.33 (+0.43%)
HIMS : 25.84 (-5.10%)
LLY : 818.02 (-2.61%)
PFE : 22.04 (-0.45%)
Viking Therapeutics Stock Pops But Struggles to Hold Gains

VKTX stock shot higher after announcing a phase 3 trial for its GLP-1 drug candidate; but investors are concerned about a lack of support in Washington

VKTX : 23.72 (-0.92%)
NVO : 58.33 (+0.43%)
LLY : 818.02 (-2.61%)
Novo Nordisk Warns Against Counterfeit Ozempic In US: Retail’s Unmoved

The company said the seized counterfeit products feature lot number PAR0362 and illegitimate serial numbers beginning with the first eight digits, 51746517.

APIE : 28.85 (-1.45%)
NVO : 58.33 (+0.43%)
AVDE : 66.05 (-0.33%)
ABBV vs. MRK: Which Drug Giant is a Better Buy Now?

Merck MRK and AbbVie ABBV are leading pharmaceutical companies with strong portfolios in oncology and immunology. While AbbVie also markets products for aesthetics, neuroscience and eye care, Merck has...

NVO : 58.33 (+0.43%)
MRK : 77.85 (-0.19%)
LLY : 818.02 (-2.61%)
ABBV : 170.16 (-1.64%)
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Popped Today

Pfizer bows, but is not entirely out of the GLP-1 race.

VKTX : 23.72 (-0.92%)
NVO : 58.33 (+0.43%)
LLY : 818.02 (-2.61%)
GPCR : 23.10 (+6.16%)
PFE : 22.04 (-0.45%)
Pharma Stocks Rebound as Trump Announces a 90-Day Pause on Tariffs

The stock market was on a roller coaster on April 9 amid the ongoing global trade war triggered by a new series of tariffs by the U.S. government. Most of the pharma bigwigs ended the trading session in...

AZN : 66.90 (-1.02%)
NVO : 58.33 (+0.43%)
LLY : 818.02 (-2.61%)
ABBV : 170.16 (-1.64%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Bagsv'rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care...

See More

Key Turning Points

3rd Resistance Point 61.72
2nd Resistance Point 60.51
1st Resistance Point 59.42
Last Price 58.33
1st Support Level 57.12
2nd Support Level 55.91
3rd Support Level 54.82

See More

52-Week High 148.15
Fibonacci 61.8% 113.33
Fibonacci 50% 102.57
Fibonacci 38.2% 91.82
Last Price 58.33
52-Week Low 57.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro